ACM
YMAB

Ashford Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Ashford Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-98,870
Closed -$482K – 93
2022
Q4 		$482K Sell
98,870
-3,100
-3% -$22.5K 0.07% 74
2022
Q3 		$1.47M Sell
101,970
-2,230
-2% -$36.9K 0.22% 54
2022
Q2 		$1.58M Sell
104,200
-2,570
-2% -$30K 0.22% 57
2022
Q1 		$1.27M Sell
106,770
-119,410
-53% -$1.23M 0.14% 74
2021
Q4 		$3.67M Sell
226,180
-225,930
-50% -$4.83M 0.37% 50
2021
Q3 		$12.9M Sell
452,110
-131,398
-23% -$4.14M 1.17% 35
2021
Q2 		$19.7M Buy
583,508
+75,425
+15% +$2.42M 1.78% 30
2021
Q1 		$15.4M Buy
508,083
+288,664
+132% +$11.8M 1.44% 34
2020
Q4 		$10.9M Buy
+219,419
New +$10.1M 1.05% 34

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Ashford Capital Management's YMAB Position: Q1 2023 in Review

Ashford Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 98,870 shares — an estimated $482K sold.

Ashford Capital Management first reported a position in YMAB in Q4 2020 and held it in 9 quarters. The position peaked at $19.7M in Q2 2021. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

  • Ashford Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ashford Capital Management sold 98,870 Y-mAbs Therapeutics shares in Q1 2023, an estimated $482K.
  • Ashford Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 9 quarters.
  • Ashford Capital Management's Y-mAbs Therapeutics position peaked at $19.7M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Ashford Capital Management's 13F filing for Q1 2023, filed 15 May 2023.